The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Shaw EG, Debinski W, Robbins ME. Central nervous system tumors. In: Gunderson LL, Tepper JE, Editors. Clinical Radiation Oncology, 2nd ed. Philadelphia, PA, USA: Elsevier Churchill Livingstone; 2007:457-493.ShawEGDebinskiWRobbinsMECentral nervous system tumorsGundersonLLTepperJEEditorsPhiladelphia, PA, USAElsevier Churchill Livingstone2007457493Search in Google Scholar
Siker ML, Donahue BR, Vogelbaum MA, Tome WA, Gilbert ML, Mehta MP. Primer intracranial neoplasms. In: Halperin EC, Perez CA, Brady LW, Editors. Principles and Practice of Radiation Oncology, 5th ed. Philadelphia, PA, USA: Wolters-Lippincott; 2008: 717-751.SikerMLDonahueBRVogelbaumMATomeWAGilbertMLMehtaMPPrimer intracranial neoplasmsHalperinECPerezCABradyLWEditorsPhiladelphia, PA, USAWolters-Lippincott2008717751Search in Google Scholar
Stieber VW, McMullen KP, Munley MT, Shaw EG. Central nervous system tumors. In: Levitt SH, Purdy JA, Perez CA, Vijayakumar S, Editors. Technical Basis of Radiation Therapy, 4th ed. Berlin, Germany: Springer; 2006: 425-453.StieberVWMcMullenKPMunleyMTShawEGCentral nervous system tumorsLevittSHPurdyJAPerezCAVijayakumarSEditorsBerlin, GermanySpringer200642545310.1007/3-540-35665-7_17Search in Google Scholar
Donahue BR. Adult gliomas. In: Lu JJ, Brady LW, Editors. Radiation Oncology - An Evidence-Based Approach, 1st ed. Berlin, Germany: Springer; 2008: 483-501.DonahueBRAdult gliomasLuJJBradyLWEditorsBerlin, GermanySpringer200848350110.1007/978-3-540-77385-6_33Search in Google Scholar
Woo SY. Central nervous system. In: Cox JD, Ang KK, Editors. Radiation Oncology. Philadelphia, PA, USA: Mosby Elsevier; 2010: 835-875.WooSYCentral nervous systemCoxJDAngKKEditorsPhiladelphia, PA, USAMosby Elsevier2010835875Search in Google Scholar
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(7): 277-300.JemalASiegelRXuJWardECancer statistics, 201060727730010.3322/caac.20073Search in Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.StuppRMasonWPvan den BentMJWellerMFisherBTaphoomMJet alRadiotherapy plus concomitant and adjuvant temozolomide for glioblastoma20053521098799610.1056/NEJMoa043330Search in Google Scholar
Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77(3): 670-676.WeilerMHartmannCWiewrodtDHerrlingerUGorliaTBährOet alChemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide201077367067610.1016/j.ijrobp.2009.05.031Search in Google Scholar
Trivedi RN, Almeida KH, Fomsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005; 65(14): 6394-6400.TrivediRNAlmeidaKHFomsaglioJLSchamusSSobolRWThe role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death200565146394640010.1158/0008-5472.CAN-05-0715Search in Google Scholar
Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995; 51: 167-223.PeggAEDolanMEMoschelRCStructure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase19955116722310.1016/S0079-6603(08)60879-XSearch in Google Scholar
Gerson SL. Clinical relevance of MGMT in the treatment of cancer.J Clin Oncol 2002;20:2388-99.GersonSLClinical relevance of MGMT in the treatment of cancer20022023889910.1200/JCO.2002.06.11011981013Search in Google Scholar
Gerson SL, Trey JE, Miller K, Berger NA. Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986; 7(5): 745-49.GersonSLTreyJEMillerKBergerNAComparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues1986757454910.1093/carcin/7.5.7453698202Search in Google Scholar
Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science. 1993; 259(5092): 219-222.DumencoLLAllayENortonKGersonSLThe prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase1993259509221922210.1126/science.84217828421782Search in Google Scholar
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25): 4189-4199.HegiMELiuLHermanJGStuppRWickWWellerMet alCorrelation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity200826254189419910.1200/JCO.2007.11.596418757334Search in Google Scholar
Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997; 17(9): 5612-5619.WattsGSPieperROCostelloJFPengYMDaltonWSFutscherBWMethylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene19971795612561910.1128/MCB.17.9.56122324099271436Search in Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003.HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMet alMGMT gene silencing and benefit from temozolomide in glioblastoma200535210997100310.1056/NEJMoa04333115758010Search in Google Scholar
Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101(1): 124-131.DunnJBaborieAAlamFJoyceKMoxhamMSibsonRet alExtent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy2009101112413110.1038/sj.bjc.6605127271369719536096Search in Google Scholar
Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glio-blastomas. Neurosurgery. 2009; 65(5): 866-875; discussion: 875.CaoVTJungTYJungSJinSGMoonKSKimIYet alThe correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glio-blastomas2009655866875discussion: 87510.1227/01.NEU.0000357325.90347.A119834398Search in Google Scholar
Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, et al. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol. 2012; 29(2): 1292-1296.TangKJinQYanWZhangWYouGLiuYet alClinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients20122921292129610.1007/s12032-011-9901-421394635Search in Google Scholar
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19): 1350-1354.EstellerMGarcia-FoncillasJAndionEGoodmanSNHidalgoOFVanaclochaVet alInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents2000343191350135410.1056/NEJM20001109343190111070098Search in Google Scholar
Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004; 10(15): 4933-4938.PazMFYaya-TurRRojas-MarcosIReynesGPollanMAguirre-CruzLet alCpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas200410154933493810.1158/1078-0432.CCR-04-039215297393Search in Google Scholar
Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, et al. Comprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM. PLoS One. 2011; 6(1): el6146.ShahNLinBSibenallerZRykenTLeeHYoonJGet alComprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM201161el614610.1371/journal.pone.0016146301754921249131Search in Google Scholar
Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Mashhad MJ, Hassanian SM, et al.. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Cell Physiol. 2018; 233(1): 378-386.BinabajMMBahramiAShahidSalesSJoodiMMashhadMJHassanianSMet alThe prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials2018233137838610.1002/jcp.2589628266716Search in Google Scholar
Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, et al. Prognostic value of 06-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. JNeurooncol. 2010; 97(3): 311-322.Karayan-TaponLQuillienVGuilhotJWagerMFromontGSaikaliSet alPrognostic value of 06-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods201097331132210.1007/s11060-009-0031-119841865Search in Google Scholar